Eri Nakamoto

Publications (2)0.39 Total impact

• Article: [Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy].

  Takashi Yokokawa, Satoshi Matsusaka, Daigo Shouji, Hiroshi Imada, Eri Nakamoto, Kayoko Kamisugi, Wataru Suzuki, Takeshi Shirai, Gou Takahashi, Kazuyoshi Kawakami, Eiji Shinozaki, Mitsukuni Suenaga, Nobuyuki Mizunuma, Kiyohiko Hatake, Toshihiro Hama
  [show abstract] [hide abstract]
  ABSTRACT: The control of delayed emesis is very important in order to continue ambulatory chemotherapy. We performed retrospective study that examined the efficacy of preventive treatment (granisetron+dexamethasone+domperidone) for delayed emesis induced by FOLFOX4 chemotherapy for advanced and recurrent colorectal cancer. The subjects were 92 patients who underwent FOLFOX4 chemotherapy at the Cancer Institute Hospital of JFCR (group with preventive treatment: 50, group without preventive treatment: 42), and the observation period was set as the 1st-9th cycle. The complete nausea inhibition rate was 50.0% in the group with and 21.5% in the group without preventive treatment, showing a significantly higher inhibition rate in the former (p=0.0047). The complete vomiting inhibition rates were 86.0% and 66.7%, respectively, again showing a significantly higher inhibition rate in the former (p=0.015). On multivariate analysis (multiple logistic analysis), the development of nausea/vomiting and preventive treatment for delayed emesis were significantly associated, showing that the treatment was an independent preventive factor. All adverse reactions induced by preventive treatment were mild, suggesting no safety-related problem. These findings suggested the usefulness of preventive treatment with granisetron, dexamethasone, and domperidone for FOLFOX4 chemotherapy-induced delayed emesis.
  Yakugaku zasshi journal of the Pharmaceutical Society of Japan 09/2009; 129(8):949-55. · 0.39 Impact Factor
• Article: [Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].

  Kayoko Kamisugi, Satoshi Matsusaka, Hiroshi Imada, Daigo Shoji, Eri Nakamoto, Takashi Yokokawa, Kazuyoshi Kawakami, Yoshimi Hirata, Kazumi Nawano, Megumi Ogawa, Eiji Shinozaki, Mitsukuni Suenaga, Nobuyuki Mizunuma, Kiyohiko Hatake, Toshihiro Hama
  [show abstract] [hide abstract]
  ABSTRACT: We have retrospectively been collecting data on adverse reactions to FOLFIRI chemotherapy in our hospital from September 2005 to August 2006, by electronic medical records. The retrospective study was of 67 patients who received FOLFIRI for advanced colorectal cancer. Survey results showed high incidences of vomiting(58.2%), anorexia(91.4%), constipation (47.8%), diarrhea (61.2%) and alopecia(71.6%). The first cycle using FOLFIRI therapy, vomiting (20.9%), anorexia(53.7%), constipation ( 14.9%), and diarrhea (23.9%)were observed. We sought to minimize inter-individual differences in pharmaceutical care and drug consultation by clinical pharmacists and to ensure the accurate understanding of patients. We are sure that this kind of activity will help us to provide better pharmaceutical care for patients.
  Gan to kagaku ryoho. Cancer & chemotherapy 09/2008; 35(8):1331-5.